Examining antibody responses in COVID-19 patients and vaccinated individuals
Association of Phenotypic Age and Antibody Titers Among SARS-Co-V2 Infected Patients and Vaccinated Groups
This study is trying to see how well the antibodies from COVID-19 infections and vaccinations work against the virus and if they change over time, especially in people with long-COVID symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 330 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Locations | 1 site (New Taipei City) |
| Trial ID | NCT05827939 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the neutralizing antibody response to SARS-CoV-2 among individuals who have been infected or vaccinated. It aims to understand how the spike protein neutralizing antibody correlates with natural infection and vaccination, as well as how mutations in viral strains affect these antibodies. The study also explores cognitive function and the decline of antibody titers over time, particularly in relation to long-COVID symptoms. A total of 97 patients from a specialized infectious pneumonia ward will be enrolled for this analysis.
Who should consider this trial
Good fit: Ideal candidates include individuals over 20 years old who have had a confirmed COVID-19 infection or have been vaccinated.
Not a fit: Patients who refuse blood draws or follow-up schedules will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of long-term immunity and inform vaccine efficacy against COVID-19.
How similar studies have performed: Other studies have shown promising results in understanding antibody responses to SARS-CoV-2, but this specific approach is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \> 20 yrs 2. Evidenced COVID-19 infeciton by PCR sequening or commercial IVD rapid test kits. (stratified by infection periods, before 2022 vs. in 2022) 3. Clealry understand the study protocol, blood drawing, organ function survey, phenoage and phenoageAccel exams and cognitive functional evaluation. 4. Agree with regular follow-up as the protocol designs Exclusion Criteria: 1. Refuse any blood draw or follow-up schedule 2. Refuse at any time 3. The PIs judges that the patient is no longer suitable to continue the study follow-up 4. Death
Where this trial is running
New Taipei City
- TuCheng Hospital — New Taipei City, Taiwan (Recruiting)
Study contacts
- Study coordinator: Chia-Hsun Hsieh, PhD
- Email: wisdom5000@gmail.com
- Phone: 0975366137
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.